The use of aromatase inhibitors in in vitro fertilization

review OA: closed public-domain-us
⚙ AI-generated summary by qwen3.7-flash, 2026-08-27 ⓘ

This paper reviews the controversial use of aromatase inhibitors in IVF for patients with endometriosis, poor response, or hyperstimulation risk, noting that efficacy requires validation through randomized trials.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The use of aromatase inhibitors (AIs) in IVF patients remains controversial. AIs can be considered for ovulation induction for IVF in women who are normal and poor responders, are at risk of ovarian hyperstimulation syndrome or thrombosis, who have endometriosis, and/or are undergoing fertility preservation procedures as a result of estrogen-dependent cancers, primarily breast and endometrial cancers. Although the biologic plausibility of the capacity of AIs in IVF patients is promising, results should be interpreted with caution, because the efficacy of AIs needs to be proven in randomized trials.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Aromatase Inhibitors Fertilization in Vitro Infertility, Female Ovulation Induction Aromatase Inhibitors Aromatase Inhibitors Combined Modality Therapy Female Fertilization in Vitro Fertilization in Vitro Humans Infertility, Female Ovulation Induction Ovulation Induction

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-09-27T09:11:36.575535+00:00
pubmed
last seen: 2026-05-13T22:15:58.344756+00:00
unpaywall
last seen: 2026-09-18T06:25:56.777850+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine